Enterprise Value
0.00
Cash
42.69M
Avg Qtr Burn
N/A
Short % of Float
5.26%
Insider Ownership
11.70%
Institutional Own.
55.08%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Seysara (Sarecycline) Details Inflammatory Acne (Acne Vulgaris) | Approved Quarterly sales | |
Nuzyra (Omadacycline) Details Bacterial infection | Approved Quarterly sales | |
Nuzyra (Omadacycline) Details Pneumonia, Community acquired bacterial pneumonia | Approved Quarterly sales | |
Omadacycline (Nuzyra) Details Intestinal infection, Stomach, Digestive tract, Nontuberculous mycobacteria infections | Phase 2b Update |